SCHEMBL1090474

SCHEMBL1090474

CCN(CC)CCCNc1nc(N2CC3CCC(CC3)C2)c2ccccc2n1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 6/20 0.52
TOP2A P11388 1/20 0.51
POLB P06746 2/20 0.49
BCHE P06276 2/20 0.47
KDM1A O60341 2/20 0.47
EHMT2 Q96KQ7 2/20 0.47
RCOR1 Q9UKL0 1/20 0.47
GAA P10253 1/20 0.46
SLC2A1 P11166 1/20 0.46
ACHE P22303 1/20 0.45
FLT3 P36888 2/20 0.45
TSHR P16473 1/20 0.45
MRGPRX1 Q96LB2 1/20 0.44
NPY1R P25929 1/20 0.44
NPY5R Q15761 1/20 0.44
RAD52 P43351 1/20 0.44
SMARCA2 P51531 1/20 0.44
KMT2A Q03164 1/20 0.44
UHRF1 Q96T88 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1089393 0.93 MRGPRX1 (0.46) CACNA2D1TOP2APOLBBCHEKDM1A
SCHEMBL1089232 0.89 BCHE (0.47) CACNA2D1TOP2APOLBBCHEKDM1A
SCHEMBL1089857 0.89 KDM1A (0.56) TOP2APOLBKDM1AEHMT2RCOR1
SCHEMBL1089720 0.88 MRGPRX1 (0.58) CACNA2D1TOP2APOLBBCHEGAA
SCHEMBL1088522 0.87 MRGPRX1 (0.57) CACNA2D1TOP2APOLBBCHEGAA
SCHEMBL1088774 0.87 MRGPRX1 (0.57) CACNA2D1TOP2APOLBBCHEGAA
SCHEMBL1090009 0.87 MRGPRX1 (0.57) CACNA2D1TOP2APOLBBCHEGAA
SCHEMBL1089603 0.84 KDM1A (0.48) TOP2APOLBKDM1AEHMT2RCOR1
SCHEMBL1090127 0.83 MRGPRX1 (0.45) POLBBCHEKDM1AEHMT2GAA
SCHEMBL2953910 0.82 CACNA2D1 (0.47) CACNA2D1TOP2APOLBBCHEKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CACNA2D1 4056/4885TOP2A 3932/4885POLB 2376/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 CACNA2D1 4056/4885TOP2A 3932/4885POLB 2376/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CACNA2D1 4056/4885TOP2A 3932/4885POLB 2376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.